[
  {
    "ts": "2025-12-02T12:00:00+00:00",
    "headline": "LifeStyles Healthcare Appoints Peter Luther to Board of Directors",
    "summary": "LifeStyles Healthcare (\"LifeStyles\"), a global intimate health and wellness platform, and Linden Capital Partners portfolio company, is pleased to announce the appointment of Peter Luther to its Board of Directors.",
    "url": "https://finance.yahoo.com/news/lifestyles-healthcare-appoints-peter-luther-120000198.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d69a3885-34dd-32c4-9136-37117b7097b5",
      "content": {
        "id": "d69a3885-34dd-32c4-9136-37117b7097b5",
        "contentType": "STORY",
        "title": "LifeStyles Healthcare Appoints Peter Luther to Board of Directors",
        "description": "",
        "summary": "LifeStyles Healthcare (\"LifeStyles\"), a global intimate health and wellness platform, and Linden Capital Partners portfolio company, is pleased to announce the appointment of Peter Luther to its Board of Directors.",
        "pubDate": "2025-12-02T12:00:00Z",
        "displayTime": "2025-12-02T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/eeab31de508f9d178b7e81d42298c1db",
          "originalWidth": 400,
          "originalHeight": 242,
          "caption": "SKYN (PRNewsfoto/SKYN)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R1_q4CF86iT6oQyOXrAGKA--~B/aD0yNDI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eeab31de508f9d178b7e81d42298c1db.cf.webp",
              "width": 400,
              "height": 242,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SqZgybaEg2omLs9.xk3KrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eeab31de508f9d178b7e81d42298c1db.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lifestyles-healthcare-appoints-peter-luther-120000198.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lifestyles-healthcare-appoints-peter-luther-120000198.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "NSRGF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T15:26:00+00:00",
    "headline": "Medication Adherence Research Report 2025: Market to Reach $3.63 Billion by 2030, Driven by Rising Chronic Disease Burden, Aging Populations, and Growing Adoption of Digital Health Tools",
    "summary": "The Global Medication Adherence Market presents opportunities driven by the rising prevalence of chronic diseases, an aging population, and healthcare tech advances, notably AI integration. Challenges include high medication costs. Key players like Johnson & Johnson and Omnicell are pivotal in this evolving landscape. Medication Adherence Market Medication Adherence Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Medication Adherence Market - Global Industry Size, Share, Trends, Opportunit",
    "url": "https://finance.yahoo.com/news/medication-adherence-research-report-2025-152600258.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7529eb5e-b981-315f-b461-9da2299d9dae",
      "content": {
        "id": "7529eb5e-b981-315f-b461-9da2299d9dae",
        "contentType": "STORY",
        "title": "Medication Adherence Research Report 2025: Market to Reach $3.63 Billion by 2030, Driven by Rising Chronic Disease Burden, Aging Populations, and Growing Adoption of Digital Health Tools",
        "description": "",
        "summary": "The Global Medication Adherence Market presents opportunities driven by the rising prevalence of chronic diseases, an aging population, and healthcare tech advances, notably AI integration. Challenges include high medication costs. Key players like Johnson & Johnson and Omnicell are pivotal in this evolving landscape. Medication Adherence Market Medication Adherence Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Medication Adherence Market - Global Industry Size, Share, Trends, Opportunit",
        "pubDate": "2025-12-02T15:26:00Z",
        "displayTime": "2025-12-02T15:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d4d79b509f8c97d21bcf63fb13b9037b",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Medication Adherence Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JQP2GKf3Nh1zAA5cmo25ZA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d4d79b509f8c97d21bcf63fb13b9037b.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z9WqsiAvWXuEyzfcpgG8Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d4d79b509f8c97d21bcf63fb13b9037b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/medication-adherence-research-report-2025-152600258.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/medication-adherence-research-report-2025-152600258.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "OMCL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T15:09:00+00:00",
    "headline": "JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis",
    "summary": "J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.",
    "url": "https://finance.yahoo.com/news/jnj-gets-eu-nod-imaavy-150900056.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0838a8bf-7f39-3b61-bd2f-0ffd575415c1",
      "content": {
        "id": "0838a8bf-7f39-3b61-bd2f-0ffd575415c1",
        "contentType": "STORY",
        "title": "JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis",
        "description": "",
        "summary": "J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.",
        "pubDate": "2025-12-02T15:09:00Z",
        "displayTime": "2025-12-02T15:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tugIemz.T.iquqxVIoxpHw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SHyaOdZAc4DXCya2O4.DtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jnj-gets-eu-nod-imaavy-150900056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jnj-gets-eu-nod-imaavy-150900056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]